XML 27 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Cash flows from operating activities    
Net loss $ (5,143,277) $ (8,104,145)
Adjustments to reconcile net loss to cash used in operating activities    
Depreciation, amortization and accretion 2,157,540 1,230,671
Stock-based compensation expense and restricted stock issuance 327,435 346,176
Derecognition of contingent consideration (5,199,806) 0
Issuance of common stock to employee 0 11,690
Derivative income (1,830) (67,989)
Changes in operating assets and liabilities:    
(Increase) in accounts receivable (3,456,364) (903,708)
(Increase) in inventory (132,199) (305,888)
(Increase) in prepaid expenses and other (171,430) (504,757)
(Increase) in other current assets (136,694) 0
Increase in accounts payable and other 2,806,973 252,113
Increase in accrued liabilities 145,467 760,798
(Decrease) increase in accrued compensation (62,729) 203,160
(Decrease) in fixed payment arrangements (216,150) 0
Increase in interest payable 0 36,164
(Decrease) in deferred rent (3,990) (1,450)
Net cash used in operating activities (9,087,054) (7,047,165)
Cash flows used in investing activities    
Deposit 0 2,888
Purchases of fixed assets 0 (12,954)
Contingent consideration payment (104,635) (50,221)
Notes receivable (1,350,000) 0
Purchase of assets (4,500,000) (800,000)
Net cash used in investing activities (5,954,635) (860,287)
Cash flows from financing activities    
Issuance of preferred, common stock and warrants 10,000,000 15,180,000
Issuance costs related to preferred, common stock and warrants (741,650) (1,479,963)
Issuance of debt 0 5,000,000
Net cash provided by financing activities 9,258,350 18,700,037
Net change in cash, restricted cash and cash equivalents (5,783,339) 10,792,585
Cash, restricted cash and cash equivalents at beginning of period 11,294,227 7,112,527
Cash, restricted cash and cash equivalents at end of period 5,510,888 17,905,112
Supplemental disclosures of cash and non-cash investing and financing transactions    
Cash paid for interest 161,890 0
Fair value of right-to-use asset and related lease liability 374,568 0
Issuance of Series G preferred stock due to acquisition of the Cerecor portfolio of pediatrics therapeutics (unaudited) 5,559,914 0
Inventory payment included in accounts payable 460,416 0
Contingent consideration included in accounts payable 16,014 0
Fixed payment arrangements included in accounts payable 291,666 0
Exchange of convertible preferred stock into common stock 319 0
Return deductions received by Cerecor 1,309,365 0
Fair value of warrants issued to investors and underwriters 0 1,888,652
Issuance of preferred stock related to purchase of asset 0 519,600
Contingent consideration related to purchase of asset $ 0 $ 8,833,219